54 results about "Blood-forming stem cell" patented technology

A process for extracting hemopoietic stem cells from the placenta of healthy puerperant to create hemopoistic stem cell bank features that the mechanical, enzyme digestive and monoclonal antibody-magnetic bead method is used to extract blood stem cells from placenta, and concentrate and purify them. Its advantages are high activity and high concentration.

The HIV-specific cytotoxic T lymphocyte (CTL) response is a critical component in controlling HIV replication and is an important part of the ultimate failure to eradicate the virus. Disclosed herein are methods for genetically enhancing the HIV-specific CTL response to allow long-term viral suppression or viral clearance. Human hematopoietic stem cells (HSCs) were genetically modified such that they differentiate into mature CTLs that will kill HIV infected cells. As disclosed herein, the functional effector cells are not human leukocyte antigen (HLA)-restricted. As disclosed herein, stem cells are transduced with non HLA-restricted chimeric antigen receptors (CARs) that allow the recognition of HIV or HIV infected cells when expressed by a CTL.

A novel induction method that effectively produces platelets from platelet precursor cells (e.g., hemopoietic stem / precursor cells) is disclosed. The method includes culturing platelet precursor cells in a culture solution in which a composite membrane is immersed so that the platelet precursor cells differentiate into platelets, the composite membrane including a porous support membrane and a porous thin membrane, the porous thin membrane being stacked on at least one side of the porous support membrane.

The invention relates to a method for separating hemopoietic stem cells through a cord blood separation double bag. According to the method provided by the invention, red blood cells and blood plasma are separated and transferred to a transfer bag step by step by adopting a main bag and the transfer bag, and a freezing protection liquid is added, the cells are transferred to a cell freezing bag and are finally frozen and stored. The method realizes the separation of the hemopoietic stem cells by adopting a centrifugal method, the structure of the adopted transfer bag for separation is simple and practical, the overall separation process is simple and convenient, the separation is totally enclosed, the pollution is reduced, the storage volume of the hemopoietic stem cells can be safely and effectively concentrated, and the recovery rate of the hemopoietic stem cells can be improved as much as possible.

The invention discloses an enlargement method of hemapoietic stem cell in the three-dimensional condition, which is characterized by the following: using calcium alginate micro-gel ball to embed the trophocytes; proceeding the together culture of embedded trophocytes and hemapoietic stem cell in the rotary wall-pattern reactor; obtaining the hemapoietic stem cell and trophocytes. The invention seperates two-source cell, which reduces the cutting force for hemapoietic stem cell effectively.

The present invention refers to a cell suspension of autologous or allogeneic, preferably autologous, adult bone marrow-derived white blood cells, preferably derived from the crest of the ilium (or iliac crest), enriched for mononuclear cells, meaning more than 25% of the white blood cells (WBCs) present in the cell suspension are mononuclear cells, and comprising:A. Mononuclear cells (MNC) selected from the list comprising or consisting of:i. A population of Lymphocytes;ii. A population of Monocytes; andiii. A population of Hematopoietic stem cells expressing CD34;and wherein the cell suspension further comprises:B. Granulocytes;for use in the treatment or amelioration of lower extremity peripheral artery disease.

The present invention relates to apparatus and method of culturing mammal cell, and is especially culturing apparatus and method for selective amplification of human stem cell, including hemopoietic stem cell. The apparatus and method of the present invention may be used widely in biological treatment of tumor and transplantation of hemopoietic stem cell.

The invention relates to a health product preparation which improves the proliferation ability of bone marrow hematopoietic stem cells to achieve the purposes of anti-aging and anti-anaemia and according to weights, the health product preparation is prepared with the following medicinal material components: 60g to 90g of donkey hide gelatin, 60g to 90g of sophora flowers, 120g to 250g of astragalus, 120g to 250g of rhizoma pollgonati, 90g to 150g of prepared radix rehmanniae, 20g to 55g of glycyrrhiza, 15g to 30g of lactose, 25g to 60g of pre-gelatinized starch and 15g to 30g of maltodextrin. The health product preparation plays the roles of strengthening human immunity, antioxidation and anti-aging, anti-anaemia and improving growth and development and has an auxiliary protection function for chemical liver injury. After being taken by various populations according to requirements, the preparation achieves the purposes of building up bodies, resisting diseases, delaying aging and improving growth and development by strengthening immunity and antioxidation function and has an auxiliary protection function for chemical liver injury, and the preparation is also beneficial to body trouble or various diseases.

The invention relates to a pharmaceutical composition for promoting hematopoiesis, which comprises hemopoietic stem cells and melanterite, wherein the preferred hemopoietic stem cells are cells which are imported with an expression vector with cell factor genes. The invention also relates to a method for preparing the pharmaceutical composition and application of the pharmaceutical composition in preparing a medicament for treating the damage state of hematopoietic function, wherein the hemopoietic stem cells and the melanterite have the function of synergistically promoting the hematopoiesis.

The present invention provides cultured immune system cells and methods of producing same. The method comprises culturing stromal cells and hemopoietic stem cells or in a chamber having a scaffolding covered or surrounded with culture medium, wherein the scaffolding allows for hemopoietic stem cells and stromal cells to have cell to cell contacts in three dimensions. The subject immune system cells are useful for screening drugs which inhibit or stimulate the immune system. The subject immune system cells are also useful in treating diseases of the immune system.

The invention provides a hematopoietic stem cell storing and pairing device, and belongs to the technical field of medical equipment. The hematopoietic stem cell storing and pairing device comprises astorage box, a take-placing opening is formed in the upper wall of the storage box, and a test tube mounting assembly and a test tube take-placing assembly are arranged in the storage box. The test tube mounting assembly comprises a storage rack and a second motor which is arranged at the bottom of the storage rack and is connected with the storage rack through a rotary shaft. The hematopoietic stem cell storing and pairing device has the advantages that taking and placing are convenient, and the storage effect is good; when a test tube needs to be taken out, the second motor drives the storage rack to rotate, the test tube needing to be taken out is moved to be below clamping plates, a driving rod drives a driving plate to move downwards, and the clamping plates are utilized for clampingthe test tube. Then the driving rod drives the driving plate and the clamping plates clamping the test tube to move upwards to the take-placing opening, the test tube can be taken out, and precise selection of the test tube is achieved; and meanwhile all test tube samples are prevented from be exposed to the external environment, and hematopoietic stem cells are prevented from being contaminatedby the external environment.

The invention relates to a method for implementing strong vivo transplantation of human induced pluripotent stem cell-derived hemopoietic stem progenitor cells. The method is induced by an MLL-AF4 single factor and has the advantages that the method is simple, convenient and efficient, human iPS (induced pluripotent stem) cells can be induced into HSC (hemopoietic stem cells) with strong vivo transplantation effects and multi-strain hemopoietic reconstruction, and many difficulties in the field are broken through. The method mainly has the advantages that the number of factors needing to be added is greatly decreased by induction with the single factor, experimental operation can be remarkably simplified, experimental efficiency is improved, the risk of gene mutation possibly induced by slow virus mediated genome insertion is avoided by a plasmid-mediated inducing method, vivo transplantation efficiency reaches up to 20% or more, medullary system bias of iPSC-HSPC in vivo is corrected,and a medullary system, a lymphoid system and an erythroid can be comprehensively reconstructed in vivo.

The invention relates to a culture medium for human peripheral blood hematopoietic stem cells, and particularly provides a culture medium for performing short-term culture on the human peripheral blood hematopoietic stem cells acquired in vitro to improve the antitumor activity of the human peripheral blood hematopoietic stem cells. The culture medium capable of improving the killing capability of the human peripheral blood hematopoietic stem cells to the tumor is characterized in that the culture medium comprises the following concrete compositions: 1000ml of Dulbecco improved basic culture medium (IMDM) containing Iscobe, 0.1 to 10mu g / ml fatty acid, 1.5mu g / ml cholesterin, 5 to 20mu g / ml glyceride, and 300mu g / ml transferring , wherein the buffer solution is sodium bicarbonate or HEPES, and the pH value of the culture medium is 7.0.

The invention provides a method for separating and purifying hemopoietic stem cells derived from umbilical cord blood and placentas and relates to a method for separating and purifying stem cells, aiming at solving the problems that a conventional hemopoietic stem cell separation and purification method only pays attention to the added amount of HES (Hydroxyethyl Starch) according to the volume ofa blood sample, and does not consider the ratio change of red blood cells in different blood samples. According to the method provided by the invention, the quantity of the red blood cells in umbilical cord blood and placenta cell suspended liquid is detected through a blood analyzer, and the HES is added according to an accurate ratio; then an accurate emission amount of the red blood cells andblood plasma, and the weight of the purified hemopoietic stem cells are realized through formula calculation and a blood flow speed controller, so that accurate adding of cryopreservation liquid is realized and the yield of the hemopoietic stem cells is maximized; separation and purification operation has rules to follow so that a condition that the adding of the HES and the cryopreservation liquid and the emission of the red blood cell plasma are carried out according to experience of people is avoided, the recycling of the hemopoietic stem cells in the samples and quality safety of the hemopoietic stem cells after being cryopreserved are ensured, and quality deviation caused by the operation of people is avoided.

The present invention provides methods for producing a viral vector comprising a membrane protein that binds to sialic acid as a component of the envelope, using neuraminidase (NA) derived from Gram-positive bacteria. The methods comprise the steps of culturing cells producing a viral vector in the presence of an NA from Gram-positive bacteria, and recovering the produced virus. The methods of this invention enable the production of high titer virus at high cost performance. Such a viral vector is capable of transferring genes at high efficiency into cells such as blood cells and hematopoietic cells, including hematopoietic stem cells, and mucous cells including mucoepithelial cells, those not amenable to gene transfer by conventional methods, and therefore should be useful as a vector for gene therapy.

The invention relates to a method of acquiring hematopoietic stem cells (HSCs) by means of three dimensional inducing system with high efficiency—which makes use of three-dimensional cell culture matrix or cell culture scaffolds, such as three-dimensional cell culture system which is made from hydrogel, seaweed and other materials, and / or associating stromal-cell including bone marrow cell, mouse bone marrow cell line OP9, OP9DL1 and so on, and / or associating multiple factors including mesoderm inducible factor, hematopoietic growth factor etc which can induce pluripotent stem cells to differentiate into hematopoietic stem cells. The invention sets up a new method of acquiring hemopoietic stem cells, establishing a system that induces pluripotent stem cells to differentiate into hemopoietic stem cells with high efficiency by means of utilizing dimensional inducing system and / or associating stromal-cell including bone marrow cell and / or multiple factors for the first time, which provide a theoretical basis and technology platform for acquiring clinical available hematopoietic stem cells, and expand additional methodologies and ideas in fields of disease mechanism exploring, drug screening etc for hematopoietic cells from pluripotent stem cells.

The invention provides a novel anti-aging and life-prolonging health care technology, which aims to realize organ function improvement, aging delay and life increase. The technology is realized through long-term multi-time transplantation of plants and proteins induced pluripotent stem cell (PPiHPS) to supplement seed cells required by growth, regeneration and restoration of body tissues and organs of individual life, and regeneratively restore ageing structures and functions of each part of individual life.

The present disclosure provides devices composed of a three-dimensional biocompatible matrix having hematopoietic stem or other progenitor cells embedded in the matrix, and a perfusable microvessel forming a lumen disposed within the matrix. The devices are useful for production of blood and cells and particles and for in vitro assays. The present disclosure also provides methods for generating blood cells.

The invention relates to application of adult stem cells in treating malignant solid tumors, in particular to application of adult stem cells in preparing a cell preparation for treating malignant solid tumors. The inventor fuses human mesenchymal stem cells and human hemopoietic stem cells respectively with human esophageal carcinoma cells, and injects the fusion cells into SCID (severe combined immune deficiency) / mice and nude mice, and as a result, the emerging rate of tumors of the fusion cells is obviously reduced and the volume thereof is also reduced. The stem cell preparation provided by the invention can obviously inhibit the growth of malignant solid tumors.

The invention provides a method for constructing a lentiviral vector with efficient transfection capacity and efficient bioactivity expression capacity. Experimental results show that the viral infection efficiency can be increased by 30-70% by using the method; in addition, the inventor unexpectedly finds that the proliferation of the T cells can also be effectively stimulated by using the technical scheme, and furthermore the treatment process of CAR-T cells is simplified, and the cost is reduced.

The invention relates the technical field of medical biology; currently, the medicines which is often used for hematopoiesis and restoring injured tissues clinically are GM-CSF, G-CSF and GM-CSF that mainly take effect on colony forming unit-granulocyte-monocyte to promote proliferation and differentiation, so as to have action on hemopoietic stem cell, medullary system multipotent progenitor cell as well as erythroid and macronucleus system hematopoiesis. But the effect of promoting hematopoiesis and proliferation of the medicines is provisional, the maintaining time is short, and the effects disappear when the medicines are stopped being taken. The invention provides a fusion protein which is used for preventing and treating hematopoiesis damage caused by radiation treatment and chemo-treatment and has the function of enhancing immunity. The gene of the SG fusion protein of the invention has the nucleotide sequence which is shown as SEQ ID NO: 4 and has the whole length of 850bp. The experiments of biology in vitro shows that the SG fusion protein of the invention can promote bone marrow colony cells to form, can effectively lead immature dendritic cells to be chemotactic, and has stronger function compared with GM-CSF.

The present invention relates to a composition for differentiating natural killer cells comprising osteopontin (OPN) as an active ingredient and a method for differentiation using the same. More precisely, osteopontin of the present invention accelerates differentiation of natural killer cells from hematopoietic stem cells and increases cytotoxic activity of natural killer cells, so that it can be effectively used as a composition for differentiating natural killer cells. OPN of the present invention regulates differentiation of natural killer cells capable of killing cancer cells, so that it can be effectively used for the treatment of cancer.

Methods for the expansion of blood stem cells and their activation as dendritic cells in a scheme for adjuvant immune therapy of patients with cancer or other diseases. The utility of combining a trade secret formulation of INCELL's M3(TM) medium in the expansion and activation of immune system stem cells and differentiated cells, including dendritic cells, with subsequent immunoreactivity against tumor cell antigens is demonstrated. The patent also describes long-term culture and cryopreservation of cells that maintain their reactivity and functionality, suggesting their potential use as universal donor cells. Furthermore, it describes how a dendritic cell activation kit can be developed using the approaches and the cell and media tools described.

The present invention refers to a cell suspension of autologous or allogeneic, preferably autologous, adult bone marrow-derived white blood cells, preferably derived from the crest of the ilium (or iliac crest), enriched for mononuclear cells, meaning more than 25% of the white blood cells (WBCs) present in the cell suspension are mononuclear cells, and comprising:A. Mononuclear cells (MNC) selected from the list comprising or consisting of:i. A population of Lymphocytes;ii. A population of Monocytes; andiii. A population of Hematopoietic stem cells expressing CD34;and wherein the cell suspension further comprises:B. Granulocytes;for use in the treatment or amelioration of lower extremity peripheral artery disease.

The invention relates to a purpose of dimethyl fumarate or a dimethyl fumarate-containing medicine composition to preparation of medicine. The medicine is used for preventing and treating acute graft versus host diseases after hemopoietic stem cell transplantation. Animal experiment study discovers that the dimethyl fumarate has the obvious effect of inhibiting the acute graft versus host diseases and can be used for preparing the medicine for preventing and treating graft versus host diseases and graft versus leukemia.

A protein designated 'SM1' has a molecular weight of about 230 kDa protein, as measured by immunoprecipitation and SDS-PAGE. SM1 proteins are present on the surface of human and mouse hematopoietic stem cells, respectively, and on primitive progenitor cells, but are absent from the surfaces of other cells, such as FDC-P1 myeloid progenitor cells, EL4 T-cells, WEHI-3 myelomonocytic cells, and 70Z / 3 pre-B lymphoid cells, or from differentiated hematopoietic cells of human cord blood or mouse bone marrow. Anti-SM1 antibody can be employed in making a preparation that is enriched for hematopoietic stem cells.

The invention discloses a novel method for preparing a nourishing layer for culturing hemopoietic stem cells. The method comprises the following steps: (1) taking a cell culture plate and coating collagen to obtain the collagen coated cell culture plate; (2) taking the hemopoietic stem cells and inoculating into the cell culture plate coated with the collagen in the step (1); culturing until the cell fusion degree is 70 percent to 90 percent and obtaining the product. The nourishing layer prepared by the method can provide powerful supporting effect on in-vitro amplification of hemopoietic stem progenitor cells (HSPC); the amplification efficiency of the HSPC is remarkably improved and the problem of the disadvantage of the HSPC can be extremely alleviated; researches and application of HSPC medical values are accelerated.